Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.
Marchand
M
M
Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. marie.marchand@bru.licr.org
Punt
C J A
CJ
Aamdal
S
S
Escudier
B
B
Kruit
W H J
WH
Keilholz
U
U
Håkansson
L
L
van Baren
N
N
Humblet
Y
Y
Mulders
P
P
Avril
M-F
MF
Eggermont
A M M
AM
Scheibenbogen
C
C
Uiters
J
J
Wanders
J
J
Delire
M
M
Boon
T
T
Stoter
G
G
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D005260:Female; D006801:Humans; D007114:Immunization; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000008:administration & dosage*; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012503:Saponins / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D008050:Lipid A; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D012503:Saponins; C472719:adjuvant SBAS-2